Holger Zimmermann
ORCID: 0000-0002-7919-4447
· 47 papers in corpus
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…